Menu
Not yet recruiting NCT07568600

Development and Clinical Study of Burn Wound Nursing Dressing Based on Sodium Hyaluronate Carbomer Composite Hydrogel

No phase Interventional Burn Burn Contracture of Skin Burn Degree Second

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: sodium hyaluronate carbomer composite hydrogel.
Who it may be relevant to
Registry conditions: Burn, Burn Contracture of Skin, Burn Degree Second. Basic parameters: 18 years — 55 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Development and Preclinical Study of Nursing Dressing for Ⅰ/Shallow Ⅱ Degree Burn Wounds Based on Sodium Hyaluronate Carbomer Composite Hydrogel

Overview

Development and clinical study of burn wound nursing dressing based on sodium hyaluronate carbomer composite hydrogel

Detailed description

Development and preclinical study of nursing dressing for Ⅰ/shallow Ⅱ degree burn wounds based on sodium hyaluronate carbomer composite hydrogel

Interventions

  • Combination product sodium hyaluronate carbomer composite hydrogel
    Development and preclinical study of nursing dressing for Ⅰ/shallow Ⅱ degree burn wounds based on sodium hyaluronate carbomer composite hydrogel

Primary outcome measures

  • Graft neo-epithelisation [Time frame: 50 days. Metric for Summarizing Data: Number and percentage of participants achieving complete neo-epithelisation by Day 50 Mean (±SD) and median (IQR) time to complete neo-epithelisation Rate of neo-epithelisation (% wound closure per day)]
Secondary outcome measures (1)
  • Pruritis [Time frame: 50 days. Metric for Summarizing Data: Mean (±SD) change from baseline in NRS score at Day 50 Median (IQR) change from baseline Number and percentage of participants with ≥ 4-point reduction or NRS ≤ 3 Median time to pruritus relief AUC of NRS scores]

Eligibility criteria

Inclusion criteria

Partial or full thickness burns requiring split thickness skin grafts Target burn wound size between 10 cm² and 1000 cm² Age ≥ 18 years Ability to read, write, and speak German Provision of voluntary informed consent to participate in the study, following a full explanation of the nature and purpose of the study, by signing the informed consent form approved by the Institutional Ethics Committee (IEC) prior to all evaluations Informed consent will be obtained from the patient or from a legal representative if the patient is not able or competent to consent; in such cases, informed consent will also be obtained from the patient when he/she regains competence Women of childbearing potential must test negative on a standard urine pregnancy test and must agree to practice appropriate contraceptive methods for the duration of the study (e.g., oral contraceptive, intrauterine device \[IUD\], intramuscular contraceptive, abstinence)

Exclusion criteria

Target wound has exposed hyaline cartilage Connective tissue disorder Previous skin graft failure at target wound site Total burn surface area ≥ 70% Infected target wound Immunosuppression therapy Chronic hemodialysis Steroid use Diabetes (Type I) Allergy or sensitivity to any of the ingredients in Prontosan® Wound Gel X Allergy or sensitivity to chlorhexidine Pregnancy Simultaneous participation in another clinical trial

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07568600 · BS-2026

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗